Author:
Gheorghe Livia,Brouwer Jorn,Wang Dee Dee,Wunderlich Nina,Rana Bushra,Rensing Benno,Eefting Frank,Timmers Leo,Swaans Martin
Abstract
Mitral regurgitation is one of the most prevalent valvulopathies worldwide, and its surgical treatment is not feasible in all cases. The elderly and frail with several comorbidities and left ventricular dysfunction are often managed conservatively. Percutaneous treatment (repair or replacement) of the mitral valve has emerged as a potential option for those patients who are at a high risk for surgery. Mitral valve repair with the Mitraclip device proved both increased safety and mortality reduction in patients with severe mitral regurgitation. On the other hand, in the last decade, percutaneous mitral replacement opened new frontiers in the field of cardiac structural interventions. There are few mitral devices; some are in the early phase of development and some are waiting for CE mark of approval. The evolution of these devices was more complicated compared to the aortic technology due to the native mitral valve's complexity and access. This review aims to provide an overview of the current devices, their specific features, and their potential complications.
Subject
Cardiology and Cardiovascular Medicine
Reference62 articles.
1. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients;Sorajja;J Am Coll Cardiol.,2019
2. Cardiovalve: device attributes implant procedure and early results;Taramasso,2019
3. FORTIS: design highlights and clinical update;Rodés-Cabau,2016
4. The HIGHLIFE program: the HIGHLIFE program: design highlights and clinical data;Piazza,2016
5. Valvular heart disease in patients ≥80 years of age;Kodali;J Am Coll Cardiol.,2018
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献